Metraipolis › archive › dc_70ecf69f139d
Belzutifan in Von Hippel-Lindau Syndrome and Renal Cell Carcinoma: Mechanisms, Clinical Evidence, and Future Directions — Europe PMC PMID:42306392
- Source
- Europe PMC (en)
- Original
- https://europepmc.org/article/MED/42306392
- DOI
- 10.7759/cureus.108967
- License (as archived)
- solo-consultazione
- Archived
- 2026-11-01T16:09:48.359Z
- SHA-256 of the archived text
b47cd03b282150216b1258f992dab01b5844e1715500be71086bfe4c10ce9f09- Stable URL of this page
https://metraipolis.com/documento/dc_70ecf69f139d
How to cite
Belzutifan in Von Hippel-Lindau Syndrome and Renal Cell Carcinoma: Mechanisms, Clinical Evidence, and Future Directions — Europe PMC PMID:42306392 — Europe PMC (en), https://europepmc.org/article/MED/42306392 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_70ecf69f139d (Metraipolis archive dc_70ecf69f139d, sha256 b47cd03b282150216b1258f992dab01b5844e1715500be71086bfe4c10ce9f09)
BibTeX
@misc{dc70ecf69f139d,
title = {Belzutifan in Von Hippel-Lindau Syndrome and Renal Cell Carcinoma: Mechanisms, Clinical Evidence, and Future Directions — Europe PMC PMID:42306392},
howpublished = {Europe PMC (en)},
url = {https://europepmc.org/article/MED/42306392},
note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_70ecf69f139d; sha256 b47cd03b282150216b1258f992dab01b5844e1715500be71086bfe4c10ce9f09},
year = {2026}
}Archived text
The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/42306392. Agents can read the archived copy with the MCP tool read_document.